Wayland Group Inc. is First to Capitalize on Pent-up UK Cannabis Investment Demand

James West
|

Wayland Group (CNSX:WAYL) (FRA:75M) (OTCMKTS:MRRCF) (formerly Maricann Group Inc.) announcement that it had secured a license to produce medical cannabis in the UK is a harbinger of opportunity in a significant new market that has the potential to generate at least as much wealth as the Canadian ACMPR movement has. So why should investors sit up and take note?

Wayland Group said it was entering the British market through the acquisition of 51% of UK-based Theros Pharma Limited for total consideration of £27.8 million (~CA$47.25 million) of which £3.8 million is paid and the rest incrementally upon certain milestones being achieved. Its an all-share deal that puts a floor value of Wayland Group’s shares at CA$1.65 per share. (Current share price at time of writing: $1.32)

Theros is well-known in the UK since it helped six-year-old Alfie Dingley receive a prescription for cannabis oil to treat epilepsy. The company is led by Professor Michael Barnes, a neurologist and medical cannabis advocate who teaches at Newcastle University.

Theros said it will import cannabis from Wayland’s Canadian operations (remember: everything for export to the UK must be EU GMP certified. (See definition here).

Think of this as the same kind of high profile seminal event that propelled Charlotte’s Web Holdings Inc. (CSE:CWEB) to its current market cap of ~$2 billion. Wayland Group’s market cap at the time of writing is ~$245 million. This marks the 5th country in which Wayland Group operates and is the 4th European operation, adding to Switzerland, Germany and Italy.

Not only is Wayland in solid company, being number 4 in an exclusive list of LP’s including Tilray, Aurora Cannabis, and Canopy Growth, who have EU GMP-certified facilities to export cannabis into the European market, but they have already got commitments to purchase cannabis from its affiliates there totalling over $30 million in sales.

The UK is an exceptional opportunity because its patients will be covered by the National Health Insurance?? System, which is certain to catalyze an absolute flood of recreational users who will suddenly develop symptoms ranging from anxiety to back pain.

Wayland Group is one of our portfolio of investment-grade cannabis companies, and provides financial support to Midas Letter in exchange for our coverage. I would add that I am personally buying the stock opportunistically on dips.

Wayland Group has come under fire previously due to inappropriate behaviour by two directors who are no longer involved with the company. The resulting fallout is precisely the cause, in my opinion, of the company’s attractive valuation.

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!